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Bordetella pertussis in infants hospitalized for
acute respiratory symptoms remains a concern
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Abstract
Background: Preliminary results suggest that pertussis infection might be considered in infants during a seasonal
respiratory syncytial virus (RSV) outbreak.
Methods: In order to analyze clinical features and laboratory findings in infants with pertussis hospitalized for acute
respiratory symptoms during a seasonal RSV outbreak, we conducted a retrospective single-center study on 19
infants with pertussis (6 boys; median age 72 days) and 19 matched controls (RSV-bronchiolitis), hospitalized from
October 2008 to April 2010. B. pertussis and RSV were detected from nasopharyngeal washes with Real Time-PCR.
Results: Infants with pertussis were less often breastfeed than infants with RSV bronchiolitis (63.2% vs 89.5%;
p <0.06). Clinically, significantly fewer infants with pertussis than controls had more episodes of whooping cough
(63.2% vs 0.0%; p < 0.001) and also less frequently fever at admission (15.8% vs 68.4%; p <0.01), apnea (52.6% vs
10.5%; p <0.006), and cyanosis (52.6% vs 10.5%; p < 0.006). Infants with pertussis had more often no abnormal chest
sounds on auscultation than infants with RSV bronchiolitis (0% vs 42,1%; p < 0.005). The absolute blood lymphocyte
and eosinophil counts were higher in infants with B. pertussis than in controls with bronchiolitis (23886 ± 16945 vs
10725 ± 4126 cells/mm3, p < 0.0001 and 13.653 ± 10.430 vs 4.730 ± 2.400 cells/mm3, p < 0.001). The molecular
analysis of 2 B. pertussis isolates for ptxA1, ptxP3, and prn2 genes showed the presence of gene variants.
Conclusions: When infants are hospitalized for acute respiratory symptoms, physicians should suspect a pertussis
infection, seek for specific clinical symptoms, investigate lymphocyte and eosinophil counts and thus diagnose
infection early enough to allow treatment.
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Background
Pertussis is a major public health problem, affecting ado-
lescents and adults as well as children. Despite a wide-
spread vaccination program, over the past fifteen years
was seen a return of pertussis worldwide [1]. Pertussis
resurgence in Europe has been attributed to an incom-
plete immunization program or to genetic changes in
Bordetella pertussis (B. pertussis). [2] The currently used
acellular pertussis vaccine contains the pertactin gene
variant prn1 and the pertussis toxin-B S1 subunit [3,4].
Molecular changes in these two genes over the past
years suggest that the antigenic divergence may make
pertussis vaccination less effective than before [5,6].
In some countries pertussis immunization is not
mandatory and in others vaccination schedules suggest
the first dose to be given at the age of 3 months. Hence,
some infants remain unimmunized or incompletely im-
munized. In those who are incompletely immunized
pertussis may develop in an atypical clinical form and
be difficult to diagnose. Pertussis can be especially diffi-
cult to diagnose in children under 1 year of age during
winter season, when other pathogens, such as respira-
tory syncytial virus (RSV), circulate. In these difficult
cases, pertussis acute respiratory symptoms can overlap
with those of bronchiolitis. A study conducted in a
group of infants hospitalized for RSV bronchiolitis
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showed that almost 2% of the patients were co-infected
with B. pertussis [7,8]. Since B. pertussis-RSV co-infection
is infrequent in young infants, physicians should keep
the possibility of co-infections in mind as to diagnose
it early and prevent bronchiolitis from becoming more
severe [9-12].
Although the standard diagnostic criterion for identify-
ing B. pertussis is culture obtained from nasal swabs or
nasopharyngeal aspirates, confirmatory information comes
nowdays from molecular techniques such as real time-
polymerase chain reaction (RT-PCR). Usually, in clinical
practice the diagnosis is generally reached without micro-
biological confirmation [13,14]. What we conspicuously
lack is the clinician’s awareness of the clinical and labora-
tory data needed to reach a suspected B. pertussis diagno-
sis in order to start treatment early.
The main purposes in our retrospective, single-center
study were to describe and compare clinical and labora-
tory features in infants with pertussis infection to infants
hospitalized for RSV bronchiolitis, and to analyze the
genetic characteristics of B. pertussis.
Methods
Patients
In a retrospective single-center study, from a group of
infants hospitalized from October 2008 to April 2010 at
our Pediatric Emergency Department for acute respiratory
symptoms we selected for study 19 consecutive infants
aged less than 12 months (6 boys, median age 72 days,
range 20-187) with Real Time-PCR confirmed pertussis.
We also analyzed data for B. pertussis variants among
hospitalized patients in whom B. pertussis was cultured.
As a control group, we recruited 19 age- and sex-matched
infants (6 boys, median age 71 days, range 20-183) from
164 infants, hospitalized during the same period with
RT-PCR confirmed RSV bronchiolitis and negative for
B. pertussis. The diagnosis of bronchiolitis was considered
in infants less than 12 months with the first episode of
acute infection of the lower respiratory tract. Infants with
co-morbidity were excluded.
Detailed demographic, clinical and laboratory data
were obtained from patients’ parents with a structured
questionnaire and from medical files. Clinical outcome
variables evaluated included gender, gestational age,
birth weight, type of delivery, DTaP (diphtheria, tetanus
and acellular pertussis) vaccination received, breast
feeding history, age and weight at admission, number of
siblings, siblings’ schooling, cough at admission (pres-
ence and duration), paroxysmal cough, presence of fever
(body temperature >37.5°C), apnea and cyanosis, chest
sounds, and hospitalization days. Laboratory outcome
variables investigated were white blood-cell count (WBC),
lymphocyte count, eosinophil count, neutrophil count,
platelet count, hemoglobin (Hb), glutamic oxaloacetic
transaminase (SGOT), glutamic pyruvic transaminase
(SGPT), gamma-glutamyl transferase (GGT) and C-
reactive protein (CRP). At hospital admission, each in-
fant was assigned a clinical severity score ranging from
0 to 8, according to respiratory rate (<45/min = 0, 45-
60/min = 1, >60/min = 2), arterial oxygen saturation in
room air (> 95% = 0, 95-90% = 1, < 90% = 2), retractions
(none = 0, present = 1, present + nasal flare = 2), and
ability to feed (normal = 0, reduced = 1, intravenous
fluid replacement =2) [15].
All infants’ parents were asked to participate in the
study and gave written informed consent. The study was
approved by the Policlinico Umberto I institutional review
board (Reference n° 2377/09.02.2012).
Nasal pharyngeal washing
From 1 to 3 days after hospitalization, all infants under-
went nasal pharyngeal washing with 3 ml of sterile saline
injected in each nostril and collected with a syringe. All
samples were delivered at room temperature within 1-2
hours to the Department of Infectious, Parasitic &
Immune-mediated Diseases at the Istituto Superiore di
Sanità Rome to identify B. pertussis and to the Molecular
Medicine Department, “Sapienza” University of Rome
(Virology Laboratory), to identify RSV.
B. pertussis detection
Pertussis was diagnosed using the Insertion Sequence
(IS) IS481, and the ptxP gene as “target” genes [16]. For
RealTime-PCR the SYBR Green Detection assay was
performed using the LightCycler 2.0 (Roche Diagnostic).
Data were analyzed with LightCycler software (version
4.0, Roche Diagnostic). All samples testing positive for
B. pertussis were confirmed with the “Bordetella Real
Time PCR” kit (Diagenode, Belgium). The specific primers
and probes for detecting B. pertussis DNA with the
commercially-available PCR kit (Diagenode, Belgium)
were selected from the literature [17].
B. pertussis isolates were cultured on charcoal agar
plates (Oxoid England) containing defibrinated sheep
blood at 10% and incubated at 35°C up to 7 days, and
inspected daily. The isolates were stored at -80°C in
medium containing brain heart infusion (BHI, Oxoid
England) supplemented with 15% glycerol. The chromo-
somal DNA from each B. pertussis strain was extracted
using the QIAamp DNA minikit (QiaGEN, Hilden,
Germany). To obtain gene molecular sequence data, the
pertussis toxin S1 subunit (ptxA), pertussis toxin promoter
(ptxP) and pertactin (prn) sequences were analyzed for
two B. pertussis clinical isolates. The used primers are
those described previously [2,18,19].
All the amplifications were done with the Mastercycler
personal thermal cycler (Eppendorff, Hamburg, Germany).
PtxA, ptxP and prn were amplified in 50 μl containing
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5 μl of PCR buffer 10X (containing 15 mM of MgCl2),
50 mM MgSO4, 0.01 mM deoxynucleotide (dNTP,
Finnzymes, Finlandia), 50 pmol of each primer and 0.5
U of HotStarTaq (QIAGEN, Hilden, Germania); 10%
dimethyl sulfoxide was added also for the prn gene.
The ptxA and ptxP genes were amplified with 35 cycles
at 94°C for 30 s; 64°C (ptxA) and 60°C (ptxP) for 30 s
and 72°C for 30 s; and the prn gene with 30 cycles at
95°C for 20 s, 55°C for 30 s and 72°C for 1 min. All
amplification products were analyzed by electrophoresis
and purified with “QIAquick purification columns” kit
(QIAGEN) for subsequent sequence analysis. Sequences
were analyzed with BLAST program. The amino acid se-
quences resulting from the nucleotide sequences were
compared using the DNAMAN program (version 5.2.10).
RSV detection
Upon arrival in the virological laboratory, the nasal wash-
ings were centrifuged to remove the mucus present in the
sample and then divided into two aliquots. The first aliquot
was used for nucleic acid extraction using a total nucleic
acid isolation kit (Roche Diagnostics, Mannheim, Germany)
and an RT-PCR panel that sought RSV and 13 more re-
spiratory viruses: influenza A and B viruses, human corona-
virus 0C43, 229E, NL-63, HUK1, adenovirus, parainfluenza
virus 1-3, human-metapneumovirus, human-Bocavirus,
and rhinovirus [14].
Statistical analysis
All data were analyzed using the SPSS program (version
17.0). Data were reported as median, range, mean,
standard deviation, and percentage. Categorical vari-
ables were analyzed with Pearson chi-square (χ2) test
and Fisher test continuous variables with the Mann-
Whitney U test. P values ≤ 0.05 were considered to indi-
cate statistical significance.
Results
No B. pertussis clustering was observed during the study.
No significant differences were found between infants
with confirmed B. pertussis and control infants with
RSV-bronchiolitis for demographic characteristics includ-
ing gender, gestational age, birth weight, type of delivery,
DTaP vaccination status, age at admission, weight on ad-
mission, presence of siblings and schooling. The percent-
age of infants who were breast fed at hospitalization was
lower in the group of infants with B. pertussis than in the
one with RSV bronchiolitis (63.2% vs 89.5%, p <0.06)
(Table 1).
Data for the clinical characteristics showed that the
percentage of infants with paroxysmal cough was sig-
nificantly higher and cough at admission lasted longer
in infants with pertussis than in control infants (63.2%
vs 0.0%, p <0.001, 7 days vs 3 days, p <0.09). The per-
centage of infants with fever (TC > 37.5°C) was signifi-
cantly lower in infants with pertussis than in the control
group (15.8% vs 68.4%, p <0.001). The percentage of in-
fants with apnea and cyanosis was significantly higher
in infants with pertussis than in those with RSV bron-
chiolitis (apnea 52.6% vs 10.5%, p <0.006 and cyanosis
52.6% vs 10.5%, p <0.006). Finally, infants with pertussis
less often had abnormal chest sounds on auscultation than
infants with RSV bronchiolitis (0% vs 42,1%; p < 0.005).
No significant difference was found between the two
groups regarding clinical severity scores [median(range)
3(0-6) vs 5(0-7)] and days hospitalization [7(2-15) vs
5(1-27)]. Clinical complications rarely arose in the two
groups: two infants in the pertussis group (10.5%) and
Table 1 Demographic characteristics of the 19 infants with pertussis and the 19 infants with RSV bronchiolitis
Demographic characteristics Infants with pertussis Infants with RSV bronchiolitis p
Age at admission (days) 71.5 ± 48.0 71.4 ± 48.0 n.s.
Male:Female 6:13 6:13 n.s.
Siblings n° (%) 14 (73.7%) 12 (63.2%) n.s.
Schooling n° (%) 11 (57.9%) 12 (63.2%) n.s.
Gestational age median in weeks (range) 40 (36-42) 39 (37-42) n.s.
Spontaneous delivery 12 (63.2%) 9 (57.9%) n.s.
Weight at birth median in kg (range) 3.220 (2.100-4.000) 3.300 (2.130- 3.850) n.s.
Weight at admission median in kg (range) 4.290 (2.820-7.850) 4.900 (3.230-7.730) n.s.
Breast feeding at admission n° (%) 12 (63.2%) 17 (89.5%) 0.06
Breast feeding median in days (range) 20 (0-150) 30 (0-94) n.s.
Vaccination (DTaP) n.s.
1st dose 4 (21.0%) 4 (21.1%)
2nd dose 1 (5.3%) 0
p values by Mann-Whitney U test.
RSV: respiratory syncytial virus.
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only one infant in the bronchiolitis group (5.3%) had
bradycardia (p = n.s.). Respiratory complications (pneumo-
thorax) arose in three of the 19 patients with pertussis
(15.8%) and in only one of the 19 with bronchiolitis (5.3%)
(p = n.s.) (Table 2). No significant differences were found
between the two groups for chest radiograph findings (air
trapping, peribronchial thickening and consolidations).
Laboratory data showed significantly higher absolute
WBC and lymphocyte numbers in children with pertussis
than in infants with RSV bronchiolitis (23886 ± 16945, vs
10725 ± 4126 cells/mm3, p <0.0001 and 13.653 ± 10.430 vs
4.730 ± 2.400 cells/mm3, p <0.001 by Mann-Whitney U
test). Finally, children with pertussis had higher absolute
blood eosinophil numbers than children with RSV bron-
chiolitis (510 ± 500 vs 86 ± 123 cells/mm3 p <0.001). No
significant differences were reported for absolute neutro-
phil numbers, absolute platelet numbers, Hb concentra-
tion, SGOT, SGPT, GGT, and CRP (Table 3).
Of the 19 infants with pertussis, four (21.0%) had re-
ceived the first DTaP vaccination dose and only one (5.3%)
had received two doses. In the control group, 4 infants
(21.0%) received the first DTaP vaccination dose (Table 1).
Of the 19 patients who tested positive for B. pertussis, 13
(68.4%) had already undergone macrolide antibiotic ther-
apy when specimens were collected, 4 (21.0%) had speci-
mens collected after antibiotic therapy, and 2 (10.5%)
received no antibiotic therapy. Three of the 19 infants with
pertussis infection (15.8%) were co-infected with RSV and
two (10.5%) with Rhinovirus. No differences were found
for clinical and demographic findings between infants with
B. pertussis infection alone and infants with B. pertussis
and RSV or RV co-infection.
Molecular analysis of pertussis cases
All 19 cases of suspected pertussis were confirmed by
molecular analysis, of which for 2 B. pertussis strains
have been isolated and analyzed for the evaluation of
molecular variants. In particular, molecular analysis de-
tected ptxA1, ptxP3 and prn2 allele variants (Table 4).
Only 2 B. Pertussis strains were cultivated because 13 in-
fants enrolled were already receiving specific antibiotic
therapy when the specimen was collected or because
technical problems arose during sample collection.
Discussion
Our retrospective single-center study identified several
demographic, clinical and laboratory features that might
help in diagnosing suspected pertussis in infants hospital-
ized for acute respiratory symptoms. Another important
finding in this study is that the B. pertussis strains circulat-
ing in our Pediatric Emergency Department seem to differ
genetically from those currently used in DTaP vaccines.
Of the 38 hospitalized infants enrolled in our study, five
with pertussis and four with bronchiolitis had already been
vaccinated. In Italy, vaccination schedule provides a first
pertussis vaccine dose at the age of 3 months, and the
booster doses at 5 and 12 months of age. This finding con-
firms previous reports, showing that many children with
pertussis have never been vaccinated against pertussis, and
Table 2 Clinical characteristics of the 19 infants with pertussis and the 19 infants with RSV bronchiolitis
Clinical characteristics Infants with pertussis Infants with RSV bronchiolitis p
Paroxysmal cough 12 (63.2%) 0 (0.0%) 0.001
Cough at admission median in days (range) 7 (0-20) 3 (0-15) 0.09
Apnea 10 (52.6%) 2 (10.5%) 0.006
Cyanosis 10 (52.6%) 2 (10.5%) 0.006
Fever (> 37.5°C) 3 (15.8%) 13 (68.4%) 0.001
Chest sounds 0.005
Rales 7 (36.8%) 11 (57.9%)
Wheeze 3 (15.8%) 2 (10.5%)
Rales and Wheeze 1 (5.3%) 6 (31.6%)
Negative 8 (42.1%) 0 (0.0%)
Severity score median (range) 3 (0-6) 5 (0-7) n.s.
Hospitalization length median in days (range) 7 (2-15) 5 (1-27) n.s.
Complications n.s.
Bradycardia 2 (10.5%) 1 (5.3%)
Respiratory 3 (15.8%) 1 (5.3%)
Total 5 (26.6%) 2 (10.5%)
p values by Mann-Whitney U test.
RSV: respiratory syncytial virus.
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that the first dose (or the first two doses) often provides
scarce protection [14,20-25].
When we analyzed our patients’ demographic data, in
line with others we found that children with whooping
cough were breastfed less frequently than those with bron-
chiolitis [26,27]. These results prevent us from conjectur-
ing whether breast feeding might protect against the risk
of B. pertussis infection in the first year of life and call for
other studies to assess this important question [27].
Our study once again confirms that clinical data can
help in diagnosing whooping cough diagnosis in infants
[12,15,28]. As expected, the hallmark clinical character-
istic specific for pertussis, is paroxysmal cough. In this
study we confirmed that other clinical signs suggesting
B. pertussis infection are episodes of apnea and cyanosis
[4,8,15,28]. On physical examination, fever is absent in
children with pertussis, and more common in patients
with bronchiolitis. In our study sample, on chest ausculta-
tion we found that over 40% of the children with pertussis
had no abnormal chest sounds, whereas all the patients in
control group had rales.
In the 19 infants hospitalized for suspected B. pertussis
we studied, when clinical features suggested whooping
cough as a diagnosis, additional proof might come
from laboratory findings showing marked lymphocyto-
sis [12,15,28,29]. Another distinctive finding was the
significantly higher eosinophil numbers in infants with
pertussis than in the control group. Since the early 1960-
1970s, research has questioned the role of B. pertussis and
its toxin in the hyper-eosinophilia response to pertussis
[30-32], but the hypothesis awaits confirmatory data from
other studies and research.
In two pertussis isolates, we undertook genetic molecu-
lar analysis to investigate gene variation in the pertussis
toxin gene (ptx), in particular its S1 subunit (ptxA), the
pertussis toxin gene promoter (ptx-P), and prn [4-6]. The
“universal” indicator for characterizing the molecular fea-
tures of B. pertussis is the catalytic subunit S1. Four S1
subunit variants have been described: S1-A (ptxA1), S1-B
(ptxA2), S1-D (ptxA3), and S1-E (ptxA4) [2,4,6,16,18,19].
Culture and molecular data allowed us to identify strains
that express the S1-A variant, whereas pertussis vaccine
contains the S1-B variant [4]. Pertactin gene polymor-
phisms reside in regions called R1 and R2. As many as
eleven different prn alleles have been identified [5,6]. Acel-
lular pertussis vaccine contains the prn-1 allele. In the two
infants whose aspirates were suitable for molecular genetic
analysis, RT-PCR identified the prn-2 gene, also found in
infants from other European countries (France and
Finland) [5,6] and in Japan [4]. We also found in both
strains the ptx-P3 variant of the pertussis toxin promoter.
This variant allows bacteria to increase toxin production
so that more severe clinical signs and symptoms manifest
[3]. Unfortunately, we were able to analyze B. pertussis
strains in only two infants because cultures were negative
in 16 infants with PCR confirmed pertussis who were
already receiving specific antibiotic therapy when speci-
mens were collected, or because technical problems arose
during sample collection.
Without seeking information from an in-depth molecu-
lar genetic analysis with standard protocols [4-6] we can-
not say whether the pertussis strain isolated from our two
patients differs immunologically from vaccine variants.
One of our two patients was 1 month old and the other 5
months old. Neither infant had been vaccinated against
pertussis nor had they received macrolides antibiotic
Table 3 Laboratory characteristics of the 19 infants with pertussis and the 19 infants with RSV bronchiolitis
Laboratory characteristics Infants with pertussis Infants with RSV bronchiolitis p
White blood cells (n/mm3) median (range) 18.760 (6.760-73790) 9.815 (4.770-20.910) 0.001
Lymphocyte count (n/mm3) median (range) 9.290 (4.320-38.665) 4.155 (1.803-8.366) 0.001
Neutrophil count (n/mm3) median (range) 4.500 (1.470-27.121) 4.170 (992-11.160) n.s.
Eosinophil count (n/mm3) median (range) 375 (14-1.770) 45 (0-527) 0.001
Hemoglobin (mg/dl) median (range) 12.1 (10.2-15.9) 11.15 (9.40-16.60) n.s.
Platelets (n/mm3) median (range) 576.000 (315.000-1.180.000) 507.000 (300.000-1.045.000) n.s.
C-reactive protein (mg/dl) median (range) 0.13 (0.01-2.35) 0.62 (0-2.35) n.s.
SGOT (UI/L) median (range) 39 (20-103) 41 (17-90) n.s.
SGPT (UI/L) median (range) 31 (13-92) 23.5 (13-60) n.s.
GGT (UI/L) median (range) 43 (13-166) 28 (7-117) n.s.
RSV: respiratory syncytial virus; SGOT: Glutamic oxaloacetic transaminase; SGPT: glutamic pyruvic transaminase; GGT: gamma-glutamyl transferase.
p values by Mann-Whitney U test.







1 1 F No No ptxA1 ptx-P3 prn-2
2 5 M No No ptxA1 ptx-P3 prn-2
ptxA1: pertussis toxin subunit 1, ptxP: pertussis toxin promoter; prn: pertactin.
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treatment at the time we collected their nasopharyngeal
aspirate specimens. Equally important, the isolates con-
tained the variant ptx-P3, known as high-producing per-
tussis toxin [31], a variant that results in increased
virulence and immune suppression. For this reason, we
cannot exclude the possibility that both infants might have
manifested the disease even if they had been vaccinated,
because the vaccine-induced immunity would not have
immunized them against the particular strain isolated.
The median age at onset in the 19 infants hospitalized
for pertussis was low (around 70 days). This finding con-
firms international evidence showing that a vaccination
strategy envisaging an additional dose at birth or maternal
immunization is advisable to prevent disease in the first
six months of life [20,28,32]. In accordance with published
data we assume that improving surveillance and diagnosis
would allow more accurate epidemiological assessments
of pertussis and help to establish better vaccination strat-
egies (times and age at vaccination).
Limitations of our study are the small number of infants
enrolled, the fact that we could analyze B. pertussis strains
in only two patients, and that nasopharyngeal washing is
not the reference standard for detecting B. pertussis in
culture.
Conclusion
In conclusion, even during seasonal RSV outbreaks the
differential diagnosis of bronchiolitis, especially in children
younger than one year, should consider whooping cough.
In the absence of exposure to ill contacts and local epi-
demiological surveillance, the major clinical factors for
diagnosing whooping cough are typical paroxysmal cough,
lymphocytosis, increased eosinophil numbers and absent
abnormal chest sounds. Molecular analysis suggests that
also in Italy B. pertussis strains differ from those included
in the current vaccine. These findings might call for a
change in the current pertussis vaccination, according also
to the current strategies in the US and other countries that
include maternal immunization with Tdap.
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